Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-Cell Treatment in Patients With Hematologic Malignancies

NCT04205409 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04205409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04205409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-Cell Treatment in Patients With Hematologic Malignancies
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
June 5, 2020
Completion date
January 5, 2026
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent grade 3a follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent non-hodgkin lymphoma, recurrent plasma cell myeloma, refractory chronic lymphocytic leukemia, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory non-hodgkin lymphoma, refractory plasma cell myeloma